Brokers Set Expectations for Bone Biologics Q3 Earnings

Bone Biologics Corp. (NASDAQ:BBLG) – Zacks Research boosted their Q3 2026 earnings per share estimates for shares of Bone Biologics in a note issued to investors on Wednesday, July 8th. Zacks Research analyst B. Sorensen now anticipates that the company will post earnings of ($0.18) per share for the quarter, up from their prior estimate of ($0.36). The consensus estimate for Bone Biologics’ current full-year earnings is ($1.52) per share. Zacks Research also issued estimates for Bone Biologics’ Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($1.17) EPS and FY2027 earnings at ($0.64) EPS.

Separately, Weiss Ratings raised Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Bone Biologics Stock Performance

Shares of BBLG stock opened at $1.38 on Friday. Bone Biologics has a 52-week low of $1.05 and a 52-week high of $4.13. The business’s fifty day moving average is $1.32 and its 200 day moving average is $1.37. The company has a market capitalization of $2.48 million, a PE ratio of -0.61 and a beta of 0.90.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.43) EPS for the quarter, hitting analysts’ consensus estimates of ($0.43).

Hedge Funds Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC grew its position in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the quarter. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 as of its most recent SEC filing. 34.30% of the stock is currently owned by institutional investors and hedge funds.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.